At the time of writing, Celldex Therapeutics Inc [CLDX] stock is trading at $27.81, up 4.27%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CLDX shares have gain 5.18% over the last week, with a monthly amount glided 12.36%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Celldex Therapeutics Inc [NASDAQ: CLDX] stock has seen the most recent analyst activity on October 21, 2025, when Mizuho initiated its Outperform rating and assigned the stock a price target of $48. Previously, Barclays started tracking the stock with Underweight rating on October 13, 2025, and set its price target to $25. On April 28, 2025, Canaccord Genuity initiated with a Buy rating and assigned a price target of $64 on the stock. Morgan Stanley started tracking the stock assigning a Overweight rating and suggested a price target of $46 on March 20, 2025. UBS initiated its recommendation with a Buy and recommended $44 as its price target on February 13, 2025. Citigroup started tracking with a Buy rating for this stock on October 07, 2024, and assigned it a price target of $70. In a note dated September 30, 2024, Goldman initiated an Neutral rating and provided a target price of $45 on this stock.
For the past year, the stock price of Celldex Therapeutics Inc fluctuated between $14.40 and $29.05. Currently, Wall Street analysts expect the stock to reach $21 within the next 12 months. Celldex Therapeutics Inc [NASDAQ: CLDX] shares were valued at $27.81 at the most recent close of the market. An investor can expect a potential drop of -24.49% based on the average CLDX price forecast.
Analyzing the CLDX fundamentals
According to Celldex Therapeutics Inc [NASDAQ:CLDX], the company’s sales were 2.60M for trailing twelve months, which represents an -100.00% plunge. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -40.54%, Pretax Profit Margin comes in at -34.47%, and Net Profit Margin reading is -34.47%. To continue investigating profitability, this company’s Return on Assets is posted at -0.29, Equity is -0.28 and Total Capital is -0.36. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 26.83 points at the first support level, and at 25.85 for the second support level. However, for the 1st resistance point, the stock is sitting at 28.64, and for the 2nd resistance point, it is at 29.47.
Ratios To Look Out For
It is important to note that Celldex Therapeutics Inc [NASDAQ:CLDX] has a current ratio of 13.01. Further, the Quick Ratio stands at 13.01, while the Cash Ratio is 0.7. Considering the valuation of this stock, the price to sales ratio is 710.75, the price to book ratio is 3.09.
Transactions by insiders
Recent insider trading involved Wright Richard M., Former Officer, that happened on Nov 13 ’25 when 49298.0 shares were sold. Officer, RICHARD M WRIGHT completed a deal on Nov 13 ’25 to buy 49298.0 shares. Meanwhile, SVP & GENERAL COUNSEL Jimenez Freddy A. sold 771.0 shares on Aug 13 ’25.
